A Formulary Management Group Consensus.
作者信息
Abu Esba Laila Carolina, Almodaimegh Hind, Ahmed Khan Mansoor, Yousef Consuela Cheriece, Al-Abdulkarim Hana, Al Aklabi Ali A, Al Harbi Mohammed
机构信息
Pharmaceutical Care Department, King Abdulaziz Medical City, Ministry of National Guard, Health Affairs, Jeddah, Saudi Arabia.
King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia.
出版信息
Glob J Qual Saf Healthc. 2024 May 2;7(2):88-94. doi: 10.36401/JQSH-23-26. eCollection 2024 May.
Abstract
摘要
相似文献
1
A Formulary Management Group Consensus.一份处方集管理小组共识。
Glob J Qual Saf Healthc. 2024 May 2;7(2):88-94. doi: 10.36401/JQSH-23-26. eCollection 2024 May.
2
Evaluation of a limited drug formulary in an adult internal medicine clinic.成人内科门诊有限药物处方集的评估
Am J Hosp Pharm. 1982 Jul;39(7):1184-6.
3
Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians.多发性硬化症治疗药物的管理方法：美国管理式医疗药剂师和医生小组的共识声明
J Manag Care Pharm. 2012 Jan-Feb;18(1):54-62. doi: 10.18553/jmcp.2012.18.1.54.
4
Formulary management guiding principles for automated systems.处方管理指导原则自动化系统。
Am J Health Syst Pharm. 2022 Sep 7;79(18):1599-1606. doi: 10.1093/ajhp/zxac123.
5
Formulary Management Activities and Practice Implications Among Public Sector Hospital Pharmaceutical and Therapeutics Committees in a South African Province.南非某省公立部门医院药物与治疗学委员会的处方集管理活动及实践意义
Front Pharmacol. 2020 Aug 18;11:1267. doi: 10.3389/fphar.2020.01267. eCollection 2020.
6
INTEGRATING HEALTH TECHNOLOGY ASSESSMENT PRINCIPLES IN FORMULARY MANAGEMENT.将卫生技术评估原则纳入处方集管理
Int J Technol Assess Health Care. 2016 Jan;32(1-2):81-7. doi: 10.1017/S0266462316000040. Epub 2016 Mar 22.
7
Formulary compliance and pharmacy labor costs associated with systematic formulary management strategy.与系统的用药目录管理策略相关的用药目录遵从性和药房人工成本。
Am J Health Syst Pharm. 2014 Mar 1;71(5):407-15. doi: 10.2146/ajhp130219.
8
The Missing Link: Evolving Accessibility To Formulary-Related Information.缺失的环节：不断发展的获取处方相关信息的途径。
P T. 2016 Nov;41(11):698-725.
9
Variation in Formulary Management Practices Within the Department of Veterans Affairs Health Care System.退伍军人事务部医疗保健系统内处方管理实践的差异。
J Manag Care Spec Pharm. 2016 Feb;22(2):114-20. doi: 10.18553/jmcp.2016.14251. Epub 2015 Dec 14.
10
Implementation of a formulary management process.实施处方集管理流程。
Am J Health Syst Pharm. 2017 Aug 15;74(16):1245-1252. doi: 10.2146/ajhp160193.
引用本文的文献
1
Real-World Experience of L-Glutamine in Sickle Cell Disease: A Retrospective Observational Study.L-谷氨酰胺治疗镰状细胞病的真实世界经验：一项回顾性观察研究。
Pharmacy (Basel). 2025 Jun 13;13(3):84. doi: 10.3390/pharmacy13030084.
本文引用的文献
1
Implementation of risk minimization measures to reduce the risk of tuberculosis among tumor necrosis factor medication users.实施风险最小化措施，以降低肿瘤坏死因子类药物使用者患结核病的风险。
Pharmacoepidemiol Drug Saf. 2024 Jan;33(1):e5682. doi: 10.1002/pds.5682. Epub 2023 Aug 24.
2
The landscape of biosimilars in Saudi Arabia: preparing for the next decade.沙特阿拉伯生物类似药的发展态势：为下一个十年做准备
Expert Opin Biol Ther. 2023 Jul-Dec;23(8):679-688. doi: 10.1080/14712598.2023.2235277. Epub 2023 Jul 28.
3
Knowledge support for environmental information on pharmaceuticals: experiences among Swedish Drug and Therapeutics Committees.药品环境信息的知识支持：瑞典药品和治疗委员会的经验。
BMC Health Serv Res. 2023 Jun 12;23(1):618. doi: 10.1186/s12913-023-09646-7.
4
Payer perceptions and use of value assessment tools in the United States.在美国，付款人对价值评估工具的认知和使用。
J Manag Care Spec Pharm. 2023 May;29(5):582-588. doi: 10.18553/jmcp.2023.29.5.582.
5
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience.比较生物类似物非格司亭与原研非格司亭在自体和异基因造血干细胞移植患者外周血造血干细胞动员、CD34+ 干细胞采集和植入中的作用：单中心经验。
Ann Transplant. 2023 Mar 3;28:e938585. doi: 10.12659/AOT.938585.
6
Designing a Value-Based Formulary for a Commercial Health Plan: A Simulated Case Study of Diabetes Medications.为商业健康计划设计基于价值的药物目录：糖尿病药物的模拟案例研究。
Value Health. 2023 Jul;26(7):1022-1031. doi: 10.1016/j.jval.2023.02.004. Epub 2023 Feb 14.
7
An Institutional Guide for Formulary Decisions of Biosimilars.生物类似药处方集决策机构指南。
Hosp Pharm. 2023 Feb;58(1):38-48. doi: 10.1177/00185787221138007. Epub 2022 Nov 29.
8
Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP).应用基于价值的策略加速新型癌症药物的可及性：来自卡塔尔肿瘤学卫生经济学专家小组（Q-OHEP）的指导。
BMC Health Serv Res. 2023 Jan 6;23(1):15. doi: 10.1186/s12913-022-08981-5.
9
Informing a cost-effectiveness threshold for Saudi Arabia.确定沙特阿拉伯的成本效益阈值。
J Med Econ. 2023 Jan-Dec;26(1):128-138. doi: 10.1080/13696998.2022.2157141.
10
Estimating Savings Opportunities From Therapeutic Substitutions of High-Cost Generic Medications.估算高价仿制药的治疗性替代带来的节省机会。
JAMA Netw Open. 2022 Nov 1;5(11):e2239868. doi: 10.1001/jamanetworkopen.2022.39868.
Zotero 插件